MedPath

A prospective observational study of temporal change in pulmonary function during epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with non-small cell lung carcinoma.

Not Applicable
Conditions
non-small cell lung carcinoma
Registration Number
JPRN-UMIN000015569
Lead Sponsor
Division of Respiratory Medicine and Clinical Allergy,Fujita Health University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
44
Inclusion Criteria

Not provided

Exclusion Criteria

1) History of thoracic radiotherapy

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The rate of change in DLCO from baseline after EGFR-TKI administration
Secondary Outcome Measures
NameTimeMethod
(1) Other spirometric parameters change (FEV1, FVC, and VC) from baseline (2) Change on thin-slice CT findings after EGFR-TKI treatment (3) Frequency and extent of adverse effect of EGFR-TKI (4) Response rate of EGFR-TKI
© Copyright 2025. All Rights Reserved by MedPath